retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Reports Retatrutide: Eli Lilly's GLP-1 Triple

Women with T2DM have a similarly high risk for pregnancy complications as pregnant women with type 1 diabetes...

Shocking Truth: Compounded GLP-1s on Groupon pose serious health risks

The global GLP-1 market is estimated to grow from USD 49.3 billion in the current year to USD 157

GLP-1RAs reduce events linked to atherogenic cardiovascular disease (especially ischemic stroke) and also renal outcomes (FLOW trial with semaglutide), with a limited effect on heart failure

Mattioli Introduction GLP-1 agonists like liraglutide have become a powerful tool for weight management, but they often come with digestive side effects and concerns about long-term use

Deal Snapshot: Novo is partnering with Ascendis on less frequently dosed drugs for metabolic diseases, committing up to $285m for a lead program, a once-monthly GLP-1 receptor agonist.